Dr. Art Taveras has been appointed president and chief scientific officer at ShangPharma Corp. Dr. Taveras brings extensive pharmaceutical leadership and technical expertise in drug discovery, chemistry R&D and pharmaceutical development, having held executive roles at pharma and biopharma companies during his 24-year career.  
 
Prior to joining the company, Dr. Taveras served as vice president Small Molecules Drug Discovery, vice president Chemistry R&D, and vice president CMC Development at Biogen Idec, leading the discovery and CMC development of neurology, immunology and oncology drug candidates at its multiple sites and partnerships in the U.S. and abroad. Dr. Taveras also served as vice president of Drug Discovery and CMC Development at Alantos Pharmaceuticals, leading the discovery research and building its Diabetes and Matrix Metalloproteinase franchise in the U.S. and Germany. Dr. Taveras began his career with Schering-Plough, where he spent 14 years in Oncology and Immunology Drug Discovery Research.
 
“We are so pleased that Dr. Taveras has joined the company,” said Michael Hui, chairman and chief executive officer of ShangPharma Corp. “His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies. Under Dr. Taveras’ leadership, there will be so much to be looking forward to.”